Alaunos Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TCRT research report →
Price Chart
About the company
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.
- CEO
- Holger Weis
- IPO
- 2005
- Employees
- 1
- HQ
- Fort Lauderdale, FL, US
Get TickerSpark's AI analysis on TCRT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.71M
- P/E
- -0.97
- PEG
- -0.03
- P/S
- 1903.84
- P/B
- 4.45
- EV/EBITDA
- -1.42
- Div Yield
- 0.00%
- Gross Margin
- -12766.67%
- Op Margin
- -121033.33%
- Net Margin
- -120766.67%
- ROE
- -286.18%
- ROIC
- -373.94%
Latest fiscal year · YoY change
- Revenue
- $5.00K-50.0%
- Gross Profit
- $-1,358,000-285.8%
- Op Income
- $-4,225,000
- Net Income
- $-4,176,000+10.8%
- EPS
- $-2.20+24.7%
- OCF Growth
- +42.3%
- FCF Growth
- +40.3%
- 52W High
- $4.50
- 52W Low
- $0.72
- 50D MA
- $1.65
- 200D MA
- $2.25
- Beta
- -1.03
- RSI (14)
- 47
- Avg Volume
- 7.56M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Alaunos said 2022 was a transformational year, highlighting a first objective clinical response, IND amendments that broadened enrollment, and a runway extension into Q4 2023 after a $15 million follow-on offering.· March 7, 2023
- First objective clinical response in the library TCR-T trial drove strong interest from physicians, patients, investors and potential partners.
- IND amendment added two new TCRs, combined screening/treatment protocols, removed repeat mutation testing after six months, and introduced cryopreservation.
- Third patient was dosed in December; management said the first three patients showed manageable safety with no DLTs or ICANS.
- The company said the library now has 12 TCRs and expects to grow to 15 this year, with Phase 2 readiness targeted by year-end.
- Cash and cost actions improved the balance sheet, with $53 million in cash at year-end and expected operating cash flows of $35 million to $40 million in 2023.
For Q4 2022, Alaunos reported a net loss of approximately $9.2 million, or $0.04 per share, versus a net loss of approximately $11.8 million, or $0.05 per share, in Q4 2021. Q4 R&D expense was approximately $5.6 million, down 32% year over year, and G&A was approximately $2.9 million, up about $800,000 year over year; operating cash burn was approximately $7.1 million, down 53% from approximately $15.1 million. For full-year 2022, net loss was approximately $37.7 million, or $0.17 per share, versus approximately $78.8 million, or $0.37 per share, in 2021. Collaboration revenue was approximately $2.9 million versus approximately $400,000 in 2021; R&D was approximately $25 million, down 50%, G&A was approximately $13.1 million, down 52%, and operating cash burn was approximately $29.2 million, down 52%. As of December 31, 2022, cash was approximately $53 million, including approximately $13.9 million of restricted cash, and outstanding debt was approximately $16.7 million. Management expects 2023 operating cash flows excluding debt service of approximately $35 million to $40 million and said cash should fund operations into Q4 2023.
Kevin Boyle Senior emphasized that 2022 was a transformational year because the company advanced its library TCR-T program into the clinic and achieved its first objective clinical response in a solid tumor. His tone was confident and promotional around the science, repeatedly framing Alaunos as a leader in non-viral TCR-T and stressing that the IND amendment should accelerate enrollment and broaden access. He also highlighted future optionality, including multiple Phase 2 trials, multiplexing, and a membrane-bound IL-15 program planned for an IND submission later this year.
Mike Wong focused on cost discipline, a stronger balance sheet, and a longer runway. He cited Q4 net loss of approximately $9.2 million, full-year net loss of approximately $37.7 million, $53 million in cash at December 31, 2022, and expected 2023 operating cash flows of approximately $35 million to $40 million excluding debt service. He also noted that the company raised approximately $15 million in gross proceeds in December and said debt stood at approximately $16.7 million, with principal repayments expected to be fully repaid by August.
Analysts focused on whether additional patients had been dosed, whether the FDA had any remaining questions on the IND amendment, and how multiplex TCR therapy would be implemented. Management said they would not report patient-by-patient updates, that there were no outstanding questions from the IND, and that multiplexing is still to be determined but looks feasible because roughly one in five prescreened patients match more than one TCR. Questions also addressed Phase 2 readiness, with management saying the key milestones are safety, maximum tolerated dose, and recommended Phase 2 dose, and asked about debt, which management said was approximately $16.7 million and expected to be repaid by August.
The call presented a clear clinical and operational catalyst path: a first objective response, three dosed patients, no DLTs or ICANS in those patients, and an IND amendment designed to speed enrollment and expand the eligible pool. Management also pointed to translational findings suggesting the cells persist, show limited exhaustion, and remain functional in tumor biopsies, which supports the platform narrative.
The program is still early, with only three patients dosed and Phase 2 readiness dependent on hitting safety and dose-finding milestones later this year. The company remains cash-burning and disclosed an outstanding debt balance of approximately $16.7 million, while several growth claims—multiplexing, IL-15, and multi-trial expansion—remain forward-looking and unproven in the clinic.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.3%
- Shares Outstanding
- 3.44M
- Float Shares
- 3.28M
of shares held by institutions
30 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 30.06K | ▲ 9.09K |
| Blackrock, Inc. | 21.35K | 0 |
| Geode Capital Management, LLC | 19.29K | ▼ 65 |
| Vanguard Fiduciary Trust Co | 15.50K | 0 |
| Vanguard Capital Management LLC | 14.06K | 0 |
| Citadel Advisors LLC | 11.87K | ▲ 1.35K |
| Osaic Holdings, Inc. | 1.67K | ▼ 66 |
| Tower Research Capital LLC (Trc) | 1.62K | ▲ 38 |
| Jones Financial Companies Lllp | 1.33K | ▲ 1.33K |
| Arax Advisory Partners | 1.22K | 0 |
| Morgan Stanley | 1.20K | ▲ 360 |
| Vanguard Global Advisers, LLC | 501 | 0 |
Held by 7 ETFs
Biggest fund positions in TCRT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 13, 26 | Fairmount Funds Management LLC | other | 0 |
| Oct 13, 26 | Fairmount Funds Management LLC | other | 0 |
| Oct 13, 26 | Fairmount Funds Management LLC | other | 0 |
| Oct 13, 26 | Fairmount Funds Management LLC | other | 0 |
| Oct 6, 26 | Weis Holger | other | 23,564 |
| Oct 6, 26 | Vieser Jaime | other | 22,669 |
| Oct 6, 26 | Postma Robert W | other | 21,829 |
| Oct 6, 26 | Jerman Michael Allen | other | 20,990 |
| Aug 6, 26 | Weis Holger | other | 4,363 |
| Jul 23, 26 | Jerman Michael Allen | other | 8,138 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TCRT coverage
Recent articles, reports, and earnings notes.
No research on TCRT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TCRT report →Alaunos Therapeutics, Inc. (TCRT) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
seekingalpha.com · Nov 17
Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?
benzinga.com · Oct 13
Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics
globenewswire.com · Oct 13
Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.
prnewswire.com · Oct 13
Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules
globenewswire.com · Sep 18
Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
benzinga.com · Sep 18
Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
globenewswire.com · May 26
Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models
globenewswire.com · May 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.